BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11408184)

  • 1. Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
    Polevaya L; Mavromoustakos T; Zoumboulakis P; Golic Grdadolnik S; Roumelioti P; Giatas N; Mutule I; Keivish T; Vlahakos DV; Iliodromitis EK; Kremastinos DT; Matsoukas J
    Bioorg Med Chem; 2001 Jun; 9(6):1639-47. PubMed ID: 11408184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.
    Roumelioti P; Polevaya L; Zoumpoulakis P; Giatas N; Mutule I; Keivish T; Zoga A; Vlahakos D; Iliodromitis E; Kremastinos D; Grdadolnik SG; Mavromoustakos T; Matsoukas J
    Bioorg Med Chem Lett; 2002 Sep; 12(18):2627-33. PubMed ID: 12182875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
    Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
    Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
    Shetty SS; DelGrande D
    J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
    Dendorfer A; Dominiak P; Tempel K; Raasch W
    J Hypertens; 2005 Oct; 23(10):1861-7. PubMed ID: 16148610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of losartan, the first angiotensin II receptor antagonist.
    Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.
    Zoumpoulakis P; Grdadolnik SG; Matsoukas J; Mavromoustakos T
    J Pharm Biomed Anal; 2002 Apr; 28(1):125-35. PubMed ID: 11861115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Losartan. The first non-peptide angiotensin II receptor antagonist for treatment of hypertension].
    Ibsen H; Rasmussen S; Slatanach R
    Ugeskr Laeger; 1996 Jun; 158(26):3798-802. PubMed ID: 8686080
    [No Abstract]   [Full Text] [Related]  

  • 12. Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
    Mavromoustakos T; Zoumpoulakis P; Kyrikou I; Zoga A; Siapi E; Zervou M; Daliani I; Dimitriou D; Pitsas A; Kamoutsis C; Laggner P
    Curr Top Med Chem; 2004; 4(4):445-59. PubMed ID: 14965311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
    Kawano H; Cody RJ; Graf K; Goetze S; Kawano Y; Schnee J; Law RE; Hsueh WA
    Hypertension; 2000 Jan; 35(1 Pt 2):273-9. PubMed ID: 10642310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
    Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Grossman E; Messerli FH; Neutel JM
    Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
    [No Abstract]   [Full Text] [Related]  

  • 16. Vinyl sulfide cyclized analogues of angiotensin II with high affinity and full agonist activity at the AT(1) receptor.
    Johannesson P; Lindeberg G; Johansson A; Nikiforovich GV; Gogoll A; Synnergren B; Le Grèves M; Nyberg F; Karlén A; Hallberg A
    J Med Chem; 2002 Apr; 45(9):1767-77. PubMed ID: 11960488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units.
    Angiolini M; Belvisi L; Poma D; Salimbeni A; Sciammetta N; Scolastico C
    Bioorg Med Chem; 1998 Nov; 6(11):2013-27. PubMed ID: 9881093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
    Schmidt B; Schieffer B
    J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme.
    Campbell DJ; Kladis A; Valentijn AJ
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):233-40. PubMed ID: 7475048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
    Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.